Method to treat endotoxin effects by administration of 33 kiloda

Details Method to treat endotoxin effects by administration of 33 kiloda Method to treat endotoxin effects by administration of 33 kiloda

1995-05-18

1997-08-19

Walsh, Stephen

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

A61K 3817

Patent

active

056588771

ABSTRACT:
Pharmaceutical compositions containing safe and effective amounts of Annexin I or 33 kDa(PLBP) can be used in a number of methods for the benefit of animals.

REFERENCES:
patent: 5201308 (1993-04-01), Newhouse
patent: 5225183 (1993-07-01), Purewal et al.
patent: 5238683 (1993-08-01), Crystal
patent: 5298489 (1994-03-01), Wallner et al.
patent: 5302581 (1994-04-01), Sarin et al.
patent: 5314890 (1994-05-01), Agostini et al.
patent: 5314992 (1994-05-01), Guyre et al.
patent: 5316915 (1994-05-01), Kraus et al.
patent: 5384128 (1995-01-01), Meezen et al.
Lacht et al. (1988) Am. J. Med. Sci. 296, 88-102.
Reutelingsperger et al., FEBS Letters 349 (1994), pp. 120-124 "Differential tissue expression of Annexin VIII in human."
Tsao FHC, et al., Biochim. Biophys. Acta 1213, 91-99 (1994) "Immunocharacterization and developmental regulation of rabbit lung calcium-dependent phospholipid-binding proteins."
Strijbos et al., Am. J. Physiol (1993) E289-E297, "Impaired febrile responses of aging mice are mediated by endogenous lipocortin-1 (annexin-1)".
Strijbos et al., Am. J. Physiol 263, (1992) E632-E636, "Inhibition of central actions of cytokines on fever and thermogenesis by lipocortin-1 involves CRF".
Das SK et al., Mol. Cellul. Biochem, 115, (1992) pp. 79-84, "Identification of calcium-dependent phospholipid-binding proteins (annexins) from guinea pig alveolar type II cells."
Keith et al., FASEB J. vol. 6 No. 4 Feb. 26, 1992, p. A1162, "Localization of phospholipid binding protein in rabbit lung".
Ambrose et al., American Journal of Respirory Cell and Molecular Biology, vol. 6 (1992) pp. 17-21, "Lipocortin I Production by Human Alveolar Macrophages."
Chung et al., Respiratory Medicine 85, 1991, 121-124 "Circulating autoantibodies to recombinant lipocortin-1 in asthma".
Perretti et al., Journal of Immunology, vol. 151, 1991 pp. 4307-4314, "Lipocortin-1 Fragments Inhibit Neutrophil Accumulation and Neutrophil-Dependent Edema in the Mouse".
Tsao FHC et al., "Lung calcium-dependent phospholipid-binding proteins: structure and function" Biochim. Biophys Acta 1081, 1991, 141-150.
Strijbos et al., American Journal of Physiological Society (1990) 11p, "Central and Peripheral Actions of Recombinant Lipocortin-1 and a Fragment of Lipocortin-1 on the Responses to Interleukin-1B".
Smith et al., Environmental Health Perspective vol. 85, 1990, pp. 135-144, "Detection of Lipocortin 1 in Human Lung Lavage Fluid; Lipocortin Degradation As a Possible Proteolytic Mechanism in the Control of Inflammatory Mediators and Inflammation".
Tsao FHC, Biochimica et Biophysica Acta. 1045 (1990) p29-39, "Purification and characterization of two rabbit lung Ca.sup.2+ -dependent phospholipid-binding proteins".
Ambrose et al., Am. J. Respir. Cell Mol. Biol. vol. 3, 1990, pp. 349-353, "Corticosteroids Increase Lipocortin I in Alveolar Epithelial Cells".
Ambrose et al., Am. J. Respir. 1990, pp. 1668-1671, "Corticosteroids increase Lipocortin I in BAL fluid from normal individuals and patients with lung disease".
Carey et al., J. Physiol 1990, R266-R269, "Lipocortin 1 fragment modifies pyrogenic actions of cytokines in rats".
Sakata et al., The Journal of Immunology vol. 145, No. 1, 1990 387-396 "The Role of Lipocortin I in Macrophage-Mediated Immunosuppresion in Tumor-Bearing Mice".
Davidson J., et al. Br. J. Pharmacol. 102, (1991) pp. 7-9, "Antipyretic actions of human recombinant lipocortin-1."
Maridonneau-Parini, I, et al. J. Clin. Invest. 83, (1989) pp. 1936-1940, "Inhibtion of O2 generation by dexamethasone is mimicked by lipocortin I in alveolar macrophages."
Perretti, M. et al. Pharmacol. Res. 30, (1994) pp. 53-59, "Cytokines, glucocorticoids and lipocortins in the control of neutrophil migration."
Cirino, G. et al. Proc. Natl. Acad, Sci. USA. 86, (1989) pp. 3428-3432, "Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test."
Relton, J. K. et al. J. Exp. Med. 174, (1991) pp. 305-310, "Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain."
Chung, K. F., et al. Respir. Med. 85, (1991) pp. 121-124, "Circulating autoantibodies to recombinant lipocortin-1 in asthma."
Perretti, M., et al. Br. J. Pharmacol. 103, (1991) pp. 1327-1332, "A novel anti-inflammatory peptide from human lipocortin 5."
Smith, S. F., et al. 151(4), (1995) p. A484, "Comparison of lipocortin 1 in human bronchoalveolar lavage (BAL) cells ex vivo and in vitro."
Drost, E. M., et al. 151(4), (1995) p. A453, "Effect of lipocortin 1 (Lcl) on human polymorphonuclear neutrophil (PMN) deformability."
Tsao, F. H. C., et al. 151(4), (1995) p. A741, "Structure and function of annexin I in human bronchoalveolar lavage fluid."

Affiliated with

Also associated with

Rating

Method to treat endotoxin effects by administration of 33 kiloda does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method to treat endotoxin effects by administration of 33 kiloda, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to treat endotoxin effects by administration of 33 kiloda will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1104769